AUTHORS
Ryotaro Nakamura, MD, Monzr M. M Al Malki, MD2, Dongyun Yang, PhD3, Sally Mokhtari, PhD4, Greta Zara, PhD5, Shanshan Tang, PhD6, Karamjeet Singh Sandhu, MD7, Amanda Blackmon, DO8, Kimberly Tran9, Anna Keryan10, Monica Torres-Coronado11, Xiu-li Li12, Katarina Piasevoli, MS13, Ketevan Gendzekhadze, PhD14, Stephen J. Forman, MD15, Nadia Carlesso, MD, PhD16, Angelo A Cardoso, MD, PhD17, Defu Zeng, MD, PhD18
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States
16 City of Hope, Duarte, California, United States
17 City of Hope, Duarte, California, United States
18 City of Hope, Duarte, California, United States
ABSTRACT
Severe aplastic anemia (SAA) is a life-threatening immune-mediated bone marrow (BM) failure syndrome. Matched-donor allogeneic hematopoietic cell transplantation (HCT) is highly effective and curative for younger patients (pts); outcomes remain suboptimal in older adults due to toxicity, infections, graft-versus-host disease (GVHD), and graft failure. Matched-donor availability and access disparities further limit curative options. We initiated a single-center pilot study (NCT05757310) evaluating COH-MC-17, a haploidentical mobilized peripheral blood (PB) stem cell graft depleted of CD4+ T cells, cryopreserved before conditioning with an unmanipulated backup graft of ≥3×106 CD34+ cells/kg, with radiation-free, non-myeloablative cyclophosphamide, pentostatin, and anti-thymocyte globulin conditioning. Primary objectives were safety, defined as primary graft failure, grade 3-4 acute GVHD, or severe organ toxicity (CTCAE V5) by day +100, and feasibility, defined by manufacturing success. Secondary endpoints were hematopoietic recovery, survival, GVHD, infections, and longitudinal donor chimerism in PB and BM. Eligible pts were >40 years with SAA, prior immunosuppressive therapy (IST), persistent or recurrent cytopenia, no cytogenetic abnormalities or detectable high-risk somatic mutations (allele frequency >5%), and no suitable matched related donor.
The enrollment goal is 7 pts. At abstract submission, 6 patient-donor pairs had consented, and 4 had been treated and completed the day +100 toxicity-evaluation window. CD4-depleted grafts were successfully manufactured from all 6 donors, meeting release criteria of ≥7.5x106 CD34+ cells/kg, ≥70% viability, ≥97% CD4+ T cell depletion, and negative sterility testing. Recipients’ median age was 71.5 years (range 42-77); 3 were ≥65 years, including 2 ≥75 years. All had prior IST without sustained response. This report focuses on early endpoints, with follow-up >1 year for the first 2 pts and >day +100 for the last enrolled pts. All pts engrafted, with median neutrophil and platelet engraftment at 14 days (range 11-15) and 17 days (range 16-18), respectively. No grade 3-4 aGvHD occurred; grade 2 aGvHD in 2 pts, and mild chronic GVHD in 1. By day +100 post-HCT, there was no protocol-defined unacceptable toxicity, one grade 3 stomatitis, per Bearman scale, due to acyclovir-resistant HSV, and no grade 4 toxicities. By day +100, viral infections/reactivations occurred in all 4 pts: CMV (n=3), HSV (n=2), and EBV (n=1). No mortality occurred within 100 days post-HCT; one patient died within the first year from sepsis at 7 months from chronic GVHD, and 2 pts >75 years died, 1 from urosepsis without active GVHD or neutropenia and 1 from pneumonia/failure to thrive.
Longitudinal short tandem repeat (STR) chimerism of total cells and lineage-sorted subsets showed rapid donor myeloid and lymphoid engraftment by days 7-15 in all patients, with near-complete/complete donor chimerism rather than anticipated mixed chimerism. Flow cytometry at day 15, with scRNA-Seq/TCR-CDR3-Seq, showed early donor T cell activation/expansion, predominantly CD8+ T cells, followed by progressive anergy/exhaustion by ~day 100. No CD4+ T cells were detectable before day 30, consistent with efficient graft CD4 depletion; CD4+ T cells recovered to 3-5% after day 30. By MLR, donor CD4+ and CD8+ T cells were hyporesponsive to pre-HCT recipient and third-party PBMC stimulation, without obvious repertoire narrowing unlike conventional HCT with GVHD.
Longitudinal BM immunophenotyping showed post-HCT remodeling of hematopoietic, immune, and stromal compartments, with early hematopoietic/myeloid reconstitution and progressive BM microenvironment restructuring. Recovery remained incomplete, with persistent primitive stem/progenitor depletion (~0.1%). T cell reconstitution showed sustained CD8+ predominance, comprising up to 93% of BM T cells, while CD4+ cells remained limited (3-11%). B cell maturation was impaired, with persistent immature CD10+ B cell expansion in BM/PB and near absence of mature CD20+ B cells (<2%) during recovery.
These early results support the feasibility and favorable initial safety of COH-MC-17 in older high-risk SAA, with successful manufacturing, reliable donor engraftment, and no grade 3-4 aGVHD. Infectious complications highlight the challenge of immune reconstitution in this older population with presumed low thymic function, supporting continued immune monitoring and regimen optimization.
DISCLOSURES
Ryotaro Nakamura, MD: Pfizer - Consultancy (Includes expert testimony); Orca Biosystems, Inc - Consultancy (Includes expert testimony); SANOFI - Consultancy (Includes expert testimony); ONO Pharmaceutical - Consultancy (Includes expert testimony)